Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546183 | 0.86 | AR (0.50) | ALDH1A1SLC22A12KDM4EHPGDAR | |
| SCHEMBL7291041 | 0.86 | AR (0.46) | ALDH1A1SLC22A12KDM4EHPGDAR | |
| SCHEMBL5901049 | 0.85 | PARP15 (0.47) | ALDH1A1SLC22A12ARMAPTUSP2 | |
| SCHEMBL5653240 | 0.85 | AR (0.45) | ALDH1A1SLC22A12ARMAPTUSP2 | |
| Hydrochloric Acid SCHEMBL10984138 | 0.85 | AR (0.49) | ALDH1A1SLC22A12KDM4EHPGDAR | |
| SCHEMBL1613328 | 0.85 | AR (0.45) | SLC22A12KDM4EAR | |
| SCHEMBL3138892 | 0.84 | SLC22A12 (0.66) | ALDH1A1SLC22A12KDM4EHPGDXDH | |
| Hydrochloric Acid SCHEMBL5900904 | 0.83 | PARP15 (0.46) | ALDH1A1SLC22A12ARMAPTUSP2 | |
| SCHEMBL17293972 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SLC22A12KDM4EXDHHTT | |
| SCHEMBL13851552 | 0.82 | HTR2A (0.43) | ALDH1A1SLC22A12ARMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040475-A | Compounds as WRN inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021254896-A1 | PROCESS FOR PREPARING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE ENABLED BY A CATALYTIC ASYMMETRIC HANTZSCH ESTER REDUCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021045879-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-4722929-A | Novel 2-phenyl-imidazoles and pharmaceutical compositions containing same | DR. KARL THOMAE GMBH (DE) | 1988-02-02 | — | — | US | disclosed |
| US-4710510-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-12-01 | — | — | US | disclosed |
| US-4696931-A | CARDIOVASCULAR DISORDERS, CARDIOTONIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | disclosed |
| US-4656171-A | 2-phenyl-imidazo-pyrazines, useful as cardiotonics | DR. KARL THOMAE GMBH (DE) | 1987-04-07 | — | — | US | disclosed |
| EP-0186010-A1 | Pyrrolo benzimidazoles, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
| US-4582837-A | Imidazo[4,5-b] and [4,5-c]pyridine derivatives having cardiotonic activity | DR. KARL THOMAE GMBH (DE) | 1986-04-15 | — | — | US | disclosed |
| EP-0166609-A2 | Aryl derivatives of heterobicyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-02 | — | — | EP | disclosed |
| EP-0149200-A1 | Novel 2-pnenyl-imidazoles, their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0148438-A2 | Imidazole derivatives, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1985-07-17 | — | — | EP | disclosed |
| EP-0098448-A2 | Imidazole derivatives, their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885SLC22A12 2204/4885KDM4E 1401/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885SLC22A12 2204/4885KDM4E 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.